Devonian Health Group, Inc. (TSE:GSD) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Devonian Health Group Inc. reported a 749% increase in fourth-quarter revenue, reaching $9 million, driven by the successful launch of its generic drug DEXLANSOPRAZOLE in Canada. The company’s annual revenue also saw a significant rise of 660%, totalling $17.8 million, despite ending the year with a net loss per share.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue